| Cediranib Demonstrates Safe, Well Tolerated Antitumour Activity in Patients ... - DG News |
|
|
DG News[Presentation title: Cediranib (Recentin) in Patients With Advanced Renal Cell Carcinoma (RCC): Final Results of a Phase II Randomised Study. ...Antiangiogenesis Agent Pazopanib Well Tolerated, Offers Clinical Benefits in ... read more |